| Project/Area Number |
20590069
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Biological pharmacy
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
SONODA Yoshiko Keio University, 薬学部, 教授 (30050743)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KASAHARA Tadashi 慶應義塾大学, 薬学部, 教授 (60049096)
TAGO Megumi 慶應義塾大学, 薬学部, 講師 (30445192)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2010: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2009: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2008: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | メラノーマ / 転移 / 接着斑キナーゼ / プロテオリピドプロテイン / PLP2 / FAK / melanoma / B16F10 / B16BL6 / metastasis / B16BL-6 |
|---|
| Research Abstract |
We established melanoma cells overexpressing proteolipid protein 2 (PLP2). We found that PLP2 enhanced adhesion, motility, and invasion in vitro, and tumor metastasis in vivo. PLP2 siRNA treatment remarkably inhibited adhesion, motility, and invasion in vitro, and prevented tumor metastasis in vivo. Furthermore, we showed that PLP2 binds PI3K, thus activating Akt.
|
